ALKERMES | ALKS - Current Liabilities


ALKERMES reported $662.09M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
AbbVie USD 41.64B 458M Jun/2026
Acadia Pharmaceuticals USD 361.44M 55.91M Jun/2026
ALKERMES USD 662.09M 62.59M Jun/2026
Amgen USD 25.5B 547M Jun/2026
Biogen USD 3.92B 918.2M Jun/2026
BioMarin Pharmaceutical USD 1.66B 870.84M Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Coherus Biosciences USD 75.51M 56.82M Jun/2026
Eli Lilly USD 47.74B 11.11B Jun/2026
Gilead Sciences USD 11.02B 1.54B Jun/2026
Heron Therapeutics USD 92.14M 1.63M Jun/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
J&J USD 54.9B 2.82B Jun/2026
Malin Corporation EUR 1000K 500K Dec/2024
Merck USD 27.73B 786M Jun/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
Otsuka Holdings JPY 738.96B 52.85B Jun/2026
Ovoca Bio EUR 1.3M 1.11M Dec/2025
Pfizer USD 32.65B 1.7B Jun/2026
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026